Hindustan Bio Sciences Analysis

dividend

Pros

Cons

• Unable to evaluate Hindustan Bio Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
• Unable to evaluate Hindustan Bio Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

health

Pros

• Hindustan Bio Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
• Hindustan Bio Sciences is profitable, therefore cash runway is not a concern.
• Hindustan Bio Sciences is profitable, therefore cash runway is not a concern.
• Interest payments on debt are well covered by earnings (EBIT is 195.2x coverage).
• Low level of unsold assets.

Cons

• Operating cash flow is negative therefore debt is not well covered.
• Debt is not covered by short term assets, assets are 0.5x debt.
• Hindustan Bio Sciences's long term commitments exceed its cash and other short term assets.
• The level of debt compared to net worth has increased over the past 5 years (6.5% vs 125.2% today).
• Hindustan Bio Sciences's level of debt (125.2%) compared to net worth is high (greater than 40%).

management

Pros

• The average tenure for the Hindustan Bio Sciences board of directors is over 10 years, this suggests they are a seasoned and experienced board.
• Jampana Venkat Rama's remuneration is lower than average for companies of similar size in India.

Cons

misc

Pros

Cons

• Hindustan Bio Sciences is not covered by any analysts.
• Hindustan Bio Sciences has significant price volatility in the past 3 months.

past

Pros

• Hindustan Bio Sciences's year on year earnings growth rate has been positive over the past 5 years.
• Hindustan Bio Sciences has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).

Cons

• Hindustan Bio Sciences has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
• Hindustan Bio Sciences used its assets less efficiently than the IN Biotechs industry average last year based on Return on Assets.
• Hindustan Bio Sciences has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
• Hindustan Bio Sciences has become profitable in the last year making it difficult to compare the Asia Biotechs industry average.

value

Pros

• Hindustan Bio Sciences is good value based on assets compared to the IN Biotechs industry average.
• BSE:532041 is up 15.8% outperforming the market in India which returned 8% over the past month.

Cons

• Hindustan Bio Sciences is overvalued based on earnings compared to the IN Biotechs industry average.
• Hindustan Bio Sciences is overvalued based on earnings compared to the India market.
• BSE:532041 is up 15.8% underperforming the Biotechs industry which returned 18.2% over the past month.